Ireland-headquartered drugmaker Shire (LSE: SHP) has had its patent upheld for Vyvanse (lisdexamfetamine) by the US Court of Appeals.
Several companies, including Actavis (NYSE: ACT) and Novartis’ (VX: NOVN) Sandoz unit were seeking Food and Drug Administration approval to market generic versions of Vyvanse. Shire filed many patent infringement lawsuits in 2011 and 2012, with the latest ruling upholding a lawsuit rendered in June 2014. It decided that 18 claims from four of the Vyvanse patents are valid and barred the defendant companies from launching Vyvanse generics until 2023 or later.
The drug was initially approved by the US FDA to treat attention-deficit hyperactivity disorder (ADHD) in children, later expanded to include an adult indication. Earlier this year it was approved for binge-eating disorder in adults.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze